PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35576171.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0832 and PMC identifier 9288489.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To explore the lower efficacy of adoptive cell transfer (ACT) therapy in patients with anti-PD-1 experienced melanoma, tumor mutational burden (TMB), predicted neoantigen frequencies, and tumor-infiltrating lymphocyte (TIL) neoantigen reactivity were assessed. Reduced neoantigen-specific TIL frequencies correlated with lower ACT response even in patients with similar TMB, suggesting a potentially harmful effect of PD-1 inhibition on T-cell outgrowth. See related article by Levi et al., p. 3042.
Medical subject headings
- Melanoma
- Neoplasms, Second Primary